Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections-Reference-Cited by-同舟云学术

Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections

Published:2019-08 Issue:8 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

McEntee Laura¹,Johnson Adam¹,Farrington Nicola¹,Unsworth Jennifer¹,Dane Aaron²,Jain Akash³,Cotroneo Nicole³,Critchley Ian³,Melnick David³,Parr Thomas³,Ambrose Paul G.⁴,Das Shampa¹^ORCID,Hope William¹⁵^ORCID

Affiliation:

1. Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool, United Kingdom

2. DaneStat Consulting, Macclesfield, United Kingdom

3. Spero Therapeutics, Cambridge, Massachusetts, USA

4. Institute for Clinical Pharmacodynamics, Schenectady, New York, USA

5. Royal Liverpool Broadgreen University Hospital Trust, Liverpool, United Kingdom

Abstract

Tebipenem pivoxil HBr (TBPM-PI-HBr) is a novel orally bioavailable carbapenem. The active moiety is tebipenem. Tebipenem pivoxil is licensed for use in Japan in children with ear, nose, and throat infections and respiratory infections. The HBr salt was designed to improve drug substance and drug product properties, including stability. TBPM-PI-HBr is now being developed as an agent for the treatment of complicated urinary tract infections (cUTI) in adults.

Funder

Spero Therapeutics

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00603-19

Reference31 articles.

1. CDC. 2013. Antibiotic resistance threats report. CDC, Atlanta, GA.

2. Bactericidal Activities of Meropenem and Ertapenem against Extended-Spectrum-β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae in a Neutropenic Mouse Thigh Model

3. Infections with Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae